Skip to main content

Table 2 Goodness of fit and model parameters for the PFS, PrePS and PPS curves

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

  Exponential Weibull Log-logistic Log-Normal Gamma Gompertz
PFS VR-CAP Intercept 7.142 7.146 6.758 6.772 7.148 3.72
Scale N/A 1.011 0.839 1.567 1.007 N/A
Shape N/A N/A N/A N/A 1.007 −0.0001
AIC 603.623 605.604 608.385 616.888 607.603 1194.398
BIC 607.116 612.590 615.371 623.874 618.082 1201.384
PFS R-CHOP Intercept 6.571 6.566 6.138 6.134 6.374 3.087
Scale N/A 0.913 0.654 1.22 1.042 N/A
Shape N/A N/A N/A N/A 0.54 −0.005
AIC 634.079 634.075 622.425 636.948 630.674 1349.269
BIC 637.576 641.070 629.419 643.942 641.166 1356.263
PrePS and PPS Intercept 7.61 6.657 7.309 7.355 7.765 4.232
PrePS VR-CAP 1.511 1.635 1.685 1.979 1.573 1.511
Pre-PS R-CHOP 1.385 1.499 1.571 1.896 1.412 1.385
Scale N/A 1.083 0.964 1.883 1.749 N/A
Shape N/A N/A N/A N/A 1.749 0.002
AIC 915.60 916.37 920.84 929.16 917.11 1717.58
BIC 932.35 937.31 941.78 950.11 942.24 1738.52
  1. Abbreviations: AIC Aikake information criterion, BIC Bayesian information criterion, PFS progression-free survival, PPS post-progression survival, PrePS pre-progression survival, R-CHOP rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone, VR-CAP bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisolone